Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single‐center prospective study in high‐risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)

@article{Thiele2011TransmissionOC,
  title={Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single‐center prospective study in high‐risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME)},
  author={Thomas Thiele and William H. Kr{\"u}ger and Kathrin Zimmermann and Till Ittermann and Antje Wessel and Ivo Steinmetz and Gottfried D{\"o}lken and Andreas Greinacher},
  journal={Transfusion},
  year={2011},
  volume={51}
}
BACKGROUND: Measures to prevent transfusion‐transmitted cytomegalovirus (TT‐CMV) infection after hematopoietic stem cell transplantation (HSCT) include transfusion of CMV antibody–negative blood units and/or transfusion of leukoreduced cellular blood products. We assessed the incidence of TT‐CMV in CMV‐seronegative patients receiving CMV‐seronegative HSC transplants, who were transfused with leukoreduced cellular blood products not tested for anti‐CMV. 
View on Wiley
pathology.ucla.edu
61 Citations
Highly Influential Citations
2
Background Citations
8
Methods Citations
1
Results Citations
4

61 Citations

Citation Type

Citation Type

Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
  • N. Kekre, M. Tokessy, +7 authors D. Sheppard
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2013
Safety of leukoreduced, cytomegalovirus (CMV)‐untested components in CMV‐negative allogeneic human progenitor cell transplant recipients
TLDR
Per institutional practice, CMV-N patients were screened for CMV IgG every 1 to 2 months pretransplant, followed by regular testing forCMV nucleic acid testing (NAT) after transplant, and underwent weekly posttransplant CMV NAT monitoring in the two study cohorts.
Transfusion in CMV seronegative T‐depleted allogeneic stem cell transplant recipients with CMV‐unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a UK dual centre experience
To establish rates of cytomegalovirus (CMV) transmission with use of CMV‐unselected (CMV‐U), leukocyte‐reduced blood components transfused to CMV‐seronegative patient/CMV‐seronegative donor (CMV…
CMV-Safe Blood Products
The impact of donor cytomegalovirus DNA on transfusion strategies for at‐risk patients
TLDR
There are no data about the prevalence of reactivations in long‐term seropositive donors compared to the incidence of window period donations in seronegative donors, and the optimal transfusion strategy for at‐risk patients is unclear.
Prevention of transfusion‐transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation
TLDR
Progress in leukoreduction technology has helped reduce the risk of TT‐CMV in hematopoietic stem cell transplantation; however, its efficacy in umbilical cord blood transplantation (CBT) has not been systematically studied.
Transfusion‐transmitted CMV infection – current knowledge and future perspectives
TLDR
No definitive data exist about the relative importance of alternative transmission routes of CMV compared to blood transfusion, and only the conduction of well‐designed studies addressing strategies to prevent TT‐CMV and the thorough examination of presumed cases of TT‐ CMV will achieve guidance for the best transfusion regimen in patients at risk.
Risk of cytomegalovirus transmission by blood products after solid organ transplantation
TLDR
No recent randomized prospective controlled trial directly compares the two CMV safety approaches for transplant recipients, so current policy relies on historic trials and more recent observational studies, and guidance is provided to inform an acceptable practice approach.
Assessment of a cytomegalovirus serology dual‐testing strategy in hematopoietic stem cell transplant recipients
  • D. Perry, M. Hakki
  • Medicine, Biology
    Transplant infectious disease : an official journal of the Transplantation Society
  • 2016
TLDR
This study assesses a recipient dual‐testing strategy before allogeneic hematopoietic stem cell transplantation to determine the most important predictor of post‐transplant CMV infection and remains associated with non‐relapse mortality.
Transfusion‐transmitted and community‐acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs
TLDR
The absence of TT‐CMV over 11 years suggests neither seronegative blood products nor CMV DNA blood donor screening would provide significant incremental safety when blood is already leukoreduced.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
TLDR
The present findings support those of prior studies showing the effectiveness of filtered unscreened blood components as an alternative transfusion support for CMV-seronegative marrow transplant recipients.
Survey of current practice for prevention of transfusion‐transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus‐seronegative
TLDR
This data indicates that transfusion practice provides two choices for transfusion of cellular blood components that reduce the risk of transfusion‐transmitted CMV (TT‐CMV): blood components collected from CMV seronegative donors and leucocyte‐reduced (LR) blood components.
Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients
TLDR
Leukoreduction of cellular blood products is an efficient method of preventing CMV infection and has been considered a safe alternative to screening donors for CMV.
A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
TLDR
It is concluded that filtration is an effective alternative to the use of seronegative blood products for prevention of transfusion-associated CMV infection in marrow transplant patients.
Direct assessment of cytomegalovirus transfusion‐transmitted risks after universal leukoreduction
TLDR
Through prospective clinical follow‐up and testing of transfusion recipients (TRs), the risk for CMV‐TTD was studied and universal leukoreduction has become one of the main strategies for the prevention of CMV-TTD.
Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
TLDR
CMV-seronegative products may be superior to leukoreduced products (particularly filtered RBCs) for the prevention of TT-CMV, and pre-emptive therapy with ganciclovir after detection of antigenemia prevented all but one case of CMV disease prior to day 100.
High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion
TLDR
Transfusion‐transmitted infection (TT‐CMV) of immunocompromised patients occurs despite the use of CMV‐seronegative or leukoreduced units, and this work aims to clarify the role of these units in the clinical practice.
Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.
TLDR
It is demonstrated that restoration of CMV-specific CTL responses may require an extended time period after BMT in some patients, and that such patients are at increased risk of developing severe CMV disease.
Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
  • E. Vamvakas
  • Biology, Medicine
    Transfusion medicine reviews
  • 2005
Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction
TLDR
Although PCR is more sensitive than antigenemia, both tests are useful in the early detection of CMV after allogeneic stem cell transplantation.
...
1
2
3
...